These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

420 related items for PubMed ID: 11030486

  • 61. Meta-analysis of randomized, double-blind, placebo-controlled, efficacy and safety studies of mirtazapine versus amitriptyline in major depression.
    Stahl S, Zivkov M, Reimitz PE, Panagides J, Hoff W.
    Acta Psychiatr Scand Suppl; 1997; 391():22-30. PubMed ID: 9265948
    [Abstract] [Full Text] [Related]

  • 62. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression.
    Fava M, Rosenbaum JF, Hoog SL, Tepner RG, Kopp JB, Nilsson ME.
    J Affect Disord; 2000 Aug; 59(2):119-26. PubMed ID: 10837880
    [Abstract] [Full Text] [Related]

  • 63. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [Abstract] [Full Text] [Related]

  • 64. A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression.
    Baldwin DS, Hawley CJ, Abed RT, Maragakis BP, Cox J, Buckingham SA, Pover GH, Ascher A.
    J Clin Psychiatry; 1996 Dec; 57 Suppl 2():46-52. PubMed ID: 8626363
    [Abstract] [Full Text] [Related]

  • 65. Mirtazapine in generalized social anxiety disorder: a randomized, double-blind, placebo-controlled study.
    Schutters SI, Van Megen HJ, Van Veen JF, Denys DA, Westenberg HG.
    Int Clin Psychopharmacol; 2010 Sep; 25(5):302-4. PubMed ID: 20715300
    [Abstract] [Full Text] [Related]

  • 66. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group.
    Thase ME.
    J Clin Psychiatry; 1997 Sep; 58(9):393-8. PubMed ID: 9378690
    [Abstract] [Full Text] [Related]

  • 67. An open-label long-term naturalistic study of mirtazapine treatment for depression in cancer patients.
    Ersoy MA, Noyan AM, Elbi H.
    Clin Drug Investig; 2008 Sep; 28(2):113-20. PubMed ID: 18211119
    [Abstract] [Full Text] [Related]

  • 68. Depressed in-patients respond differently to imipramine and mirtazapine.
    Bruijn JA, Moleman P, Mulder PG, van den Broek WW.
    Pharmacopsychiatry; 1999 May; 32(3):87-92. PubMed ID: 10463374
    [Abstract] [Full Text] [Related]

  • 69. [Comparative study of paroxetine and mianserin in depression in elderly patients: efficacy, tolerance, serotonin dependence].
    Daléry J, Aubin V.
    Encephale; 2001 May; 27(1):71-81. PubMed ID: 11294041
    [Abstract] [Full Text] [Related]

  • 70. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression.
    Murphy GM, Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF.
    Arch Gen Psychiatry; 2004 Nov; 61(11):1163-9. PubMed ID: 15520364
    [Abstract] [Full Text] [Related]

  • 71. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II).
    McElroy SL, Weisler RH, Chang W, Olausson B, Paulsson B, Brecher M, Agambaram V, Merideth C, Nordenhem A, Young AH, EMBOLDEN II (Trial D1447C00134) Investigators.
    J Clin Psychiatry; 2010 Feb; 71(2):163-74. PubMed ID: 20122366
    [Abstract] [Full Text] [Related]

  • 72. Effect of mirtazapine on thyroid hormones in adult patients with major depression.
    Gambi F, De Berardis D, Sepede G, Campanella D, Galliani N, Carano A, La Rovere L, Salini G, Penna L, Cicconetti A, Spinella S, Quartesan R, Salerno RM, Ferro FM.
    Int J Immunopathol Pharmacol; 2005 Feb; 18(4):737-44. PubMed ID: 16388723
    [Abstract] [Full Text] [Related]

  • 73. An overview of the clinical efficacy of mirtazapine.
    Benkert O, Muller M, Szegedi A.
    Hum Psychopharmacol; 2002 Jun; 17 Suppl 1():S23-6. PubMed ID: 12404666
    [Abstract] [Full Text] [Related]

  • 74. Paroxetine augmentation in patients with generalised social anxiety disorder, non-responsive to mirtazapine or placebo.
    Schutters SI, van Megen HJ, Van Veen JF, Schruers KR, Westenberg HG.
    Hum Psychopharmacol; 2011 Jan; 26(1):72-6. PubMed ID: 23055414
    [Abstract] [Full Text] [Related]

  • 75. Whether to increase or maintain dosage of mirtazapine in early nonimprovers with depression.
    Ueno F, Nakajima S, Suzuki T, Abe T, Sato Y, Mimura M, Uchida H.
    J Clin Psychiatry; 2015 Apr; 76(4):434-9. PubMed ID: 25919835
    [Abstract] [Full Text] [Related]

  • 76. Mirtazapine orally disintegrating tablets in depressed nursing home residents 85 years of age and older.
    Nelson JC, Hollander SB, Betzel J, Smolen P, Mirtazapine Nursing Home Study Group.
    Int J Geriatr Psychiatry; 2006 Sep; 21(9):898-901. PubMed ID: 16955423
    [Abstract] [Full Text] [Related]

  • 77. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study.
    Blier P, Ward HE, Tremblay P, Laberge L, Hébert C, Bergeron R.
    Am J Psychiatry; 2010 Mar; 167(3):281-8. PubMed ID: 20008946
    [Abstract] [Full Text] [Related]

  • 78.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 79. Efficacy, tolerability, and preference of mirtazapine orally disintegrating tablets in depressed patients: a 17-week naturalistic study in Lithuania.
    Danileviciūte V, Sveikata A, Adomaitiene V, Gumbrevicius G, Fokas V, Sveikatiene R.
    Medicina (Kaunas); 2009 Mar; 45(10):778-84. PubMed ID: 19996664
    [Abstract] [Full Text] [Related]

  • 80.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.